Drugs / RDX227675
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03018067 | Jan → May 2017 | — | Ardelyx | Terminated | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2016-06-22 | Ardelyx | Results Ardelyx Reports Progress of Development Programs ardelyx.com ↗
Additionally, the Company today announced the results of a pharmacodynamic (PD) study evaluating once daily (QD) dosing of its product candidate, RDX227675, for the treatment of hyperkalemia. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2016-08-01 | Ardelyx | Ardelyx Receives Notice of Allowance of Composition of Matter Patent Covering its Novel Potassium Binder RDX227675 ardelyx.com ↗ |
| 2016-06-22 | Ardelyx | Ardelyx Reports Progress of Development Programs ardelyx.com ↗ |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RDX227675 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03018067 ↗ |